Home › Obesity › California › Anaheim
Obesity clinical trials in Anaheim, CA
4 studies for Obesity are looking for participants at sites in and around Anaheim (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
RecruitingPhase 3
- Smart Cures Clinical Research, Anaheim
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
RecruitingPhase 3
- Smart Cures Clinical Research, Anaheim
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
RecruitingPhase 1
- CenExel Act- Anaheim Clinical Trials /ID# 283200, Anaheim
A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
RecruitingPhase 2
- Anaheim Clinical Trials, Anaheim
About Obesity
Read about the causes of obesity and find out what you can do to decrease your risk of its associated health issues.
More about Obesity on MedlinePlus
Obesity trials in other cities
- Houston, TX43 studies
- Chicago, IL41 studies
- New York City, NY40 studies
- San Antonio, TX40 studies
- Washington, DC33 studies
- Orlando, FL31 studies
- Dallas, TX30 studies
- Boston, MA28 studies
- Las Vegas, NV27 studies
- Miami, FL27 studies
- Baltimore, MD25 studies
- Jacksonville, FL25 studies
Other studies in Anaheim
- Schizophrenia8 studies
- Non-Small Cell Lung Cancer8 studies
- Alzheimer's Disease7 studies
- Ulcerative Colitis7 studies
- Crohn's Disease6 studies
- Breast Cancer5 studies
- Lung Cancer4 studies
- Bipolar Disorder4 studies
- Psychotic Disorders4 studies
- Migraine4 studies
- Irritable Bowel Syndrome3 studies
- Metastatic Cancer3 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.